Jazz Pharmaceuticals plc affirmed earnings guidance for the full year 2024. For the year, the company expected revenues to be in the range of $4,000 million to $4,200 million, net income of $385 million to $530 million and net income per diluted share to be in the range of $5.80 to $7.70.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
110.5 USD | +0.68% | -2.32% | -10.17% |
13/05 | US reclassification could drive fresh research funding into pot sector | RE |
07/05 | Jazz Pharmaceuticals Insider Sold Shares Worth $548,250, According to a Recent SEC Filing | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.17% | 6.97B | |
+32.36% | 694B | |
+31.00% | 593B | |
-1.60% | 371B | |
+20.07% | 331B | |
+6.04% | 290B | |
+14.81% | 239B | |
+10.17% | 209B | |
-2.94% | 209B | |
+9.27% | 169B |
- Stock Market
- Equities
- JAZZ Stock
- News Jazz Pharmaceuticals plc
- Jazz Pharmaceuticals plc Affirms Earnings Guidance for the Full Year 2024